/
Medicinal chemicals & botanical products company · Z4 · FY ends Mar · Revenue C$278M · -30.22% margin · -C$86M FCF
C$1.22
C$0.16 (-11.59%)
Price from 43 days ago
The business is unprofitable at the operating level (-43.55% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 9.5% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -C$177M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
C$278M
▼ -9.5% YoY
Net Income (TTM)
-C$327M
▲ +9.0% YoY
Op. Margin
-30.22%
▲ +33.4pp YoY
ROIC
-7.45%
▲ +1.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-C$86M
▲ +38.1% YoY
Op. Cash Flow (TTM)
-C$79M
▲ +41.2% YoY
Net Debt
-C$146M
Net Cash Position
Cash & Equiv.
C$371M
5Y CAGR: -7.6%
Continue Research